Korean Red Ginseng enhances cardiac hemodynamics on doxorubicin-induced toxicity in rats.
Antioxidant
Cardioprotection
Doxorubicin
Hemodynamics
Korean Red Ginseng
Journal
Journal of ginseng research
ISSN: 1226-8453
Titre abrégé: J Ginseng Res
Pays: Korea (South)
ID NLM: 100890690
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
28
08
2018
revised:
07
03
2019
accepted:
08
03
2019
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
ppublish
Résumé
Korean Red Ginseng (KRG) has been known to possess many ginsenosides. These ginsenosides are used for curing cardiovascular problems. The present study show the protective potential of KRG against doxorubicin (DOX)-induced myocardial dysfunction, by assessing electrocardiographic, hemodynamic, and biochemical parameters and histopathological findings. Animals were fed a standard chow and adjusted to their environment for 3 days before the experiments. Next, the rats were equally divided into five groups (n = 9, each group). The animals were administered with KRG (250 and 500 mg/kg) for 10 days and injected with DOX (20 mg/kg, subcutaneously, twice at a 24-h interval) on the 8th and 9th day. Electrocardiography and echocardiography were performed to study hemodynamics. Plasma levels of superoxide dismutase, catalase, glutathione peroxidase, and malondialdehyde were measured. In addition, the dose of troponin I and activity of myeloperoxidase in serum and cardiac tissue were analyzed, and the histopathological findings were evaluated using light microscopy. Administration of KRG at a dose of 250 and 500 mg/kg recovered electrocardiographic changes, ejection fraction, fractional shortening, left ventricular systolic pressure, the maximal rate of change in left ventricle contraction (+dP/dt These mean that KRG mitigates myocardial damage by modulating the hemodynamics, histopathological abnormality, and oxidative stress related to DOX-induced cardiomyopathy in rats. The results of the present study show protective effects of KRG on cardiac toxicity.
Sections du résumé
BACKGROUND
BACKGROUND
Korean Red Ginseng (KRG) has been known to possess many ginsenosides. These ginsenosides are used for curing cardiovascular problems. The present study show the protective potential of KRG against doxorubicin (DOX)-induced myocardial dysfunction, by assessing electrocardiographic, hemodynamic, and biochemical parameters and histopathological findings.
METHODS
METHODS
Animals were fed a standard chow and adjusted to their environment for 3 days before the experiments. Next, the rats were equally divided into five groups (n = 9, each group). The animals were administered with KRG (250 and 500 mg/kg) for 10 days and injected with DOX (20 mg/kg, subcutaneously, twice at a 24-h interval) on the 8th and 9th day. Electrocardiography and echocardiography were performed to study hemodynamics. Plasma levels of superoxide dismutase, catalase, glutathione peroxidase, and malondialdehyde were measured. In addition, the dose of troponin I and activity of myeloperoxidase in serum and cardiac tissue were analyzed, and the histopathological findings were evaluated using light microscopy.
RESULTS
RESULTS
Administration of KRG at a dose of 250 and 500 mg/kg recovered electrocardiographic changes, ejection fraction, fractional shortening, left ventricular systolic pressure, the maximal rate of change in left ventricle contraction (+dP/dt
CONCLUSION
CONCLUSIONS
These mean that KRG mitigates myocardial damage by modulating the hemodynamics, histopathological abnormality, and oxidative stress related to DOX-induced cardiomyopathy in rats. The results of the present study show protective effects of KRG on cardiac toxicity.
Identifiants
pubmed: 32372870
doi: 10.1016/j.jgr.2019.03.002
pii: S1226-8453(18)30285-9
pmc: PMC7195579
doi:
Types de publication
Journal Article
Langues
eng
Pagination
483-489Informations de copyright
© 2019 The Korean Society of Ginseng, Published by Elsevier Korea LLC.
Références
Cardiovasc Toxicol. 2005;5(3):257-67
pubmed: 16244371
J Mol Cell Cardiol. 1987 Aug;19(8):817-28
pubmed: 3320376
Cardiovasc Toxicol. 2007;7(2):154-9
pubmed: 17652822
J Biol Chem. 1972 May 25;247(10):3170-5
pubmed: 4623845
J Ginseng Res. 2012 Jul;36(3):248-55
pubmed: 23717125
Korean J Physiol Pharmacol. 2013 Aug;17(4):283-9
pubmed: 23946687
Cancer Res. 1993 Oct 1;53(19):4658-64
pubmed: 8402643
Pharmacol Res. 1998 Oct;38(4):297-303
pubmed: 9774493
J Med Food. 2014 Jan;17(1):111-8
pubmed: 24456361
Pharmacol Rev. 2004 Jun;56(2):185-229
pubmed: 15169927
J Card Surg. 1997 May-Jun;12(3):133-7; discussion 138
pubmed: 9395941
Cardiovasc Toxicol. 2014 Jun;14(2):153-61
pubmed: 24343415
Anadolu Kardiyol Derg. 2007 Dec;7(4):404-10
pubmed: 18065337
J Ginseng Res. 2015 Jul;39(3):206-12
pubmed: 26199551
Lab Anim. 2006 Apr;40(2):153-71
pubmed: 16600075
FASEB J. 1997 Oct;11(12):931-6
pubmed: 9337145
Mol Cell Biochem. 2006 Apr;285(1-2):149-54
pubmed: 16612575
Cardiovasc Hematol Disord Drug Targets. 2018;18(3):224-233
pubmed: 29623860
Science. 1973 Feb 9;179(4073):588-90
pubmed: 4686466
J Pharmacol Methods. 1985 Nov;14(3):157-67
pubmed: 2997548
FASEB J. 1990 Oct;4(13):3076-86
pubmed: 2210154
N Engl J Med. 1998 Sep 24;339(13):900-5
pubmed: 9744975
Life Sci. 2002 Apr 5;70(20):2377-89
pubmed: 12150202
J Chromatogr A. 2001 Jul 6;921(2):335-9
pubmed: 11471818
J Pharmacol Toxicol Methods. 1993 Oct;30(2):55-67
pubmed: 8298182
Am J Physiol Heart Circ Physiol. 2002 Oct;283(4):H1656-61
pubmed: 12234820
Anticancer Drugs. 2007 Apr;18(4):493-8
pubmed: 17351403
Pharm Biol. 2013 Mar;51(3):339-44
pubmed: 23134235
J Ginseng Res. 2013 Jul;37(3):273-82
pubmed: 24198652
Toxicol Sci. 2011 May;121(1):11-30
pubmed: 21278051
J Am Assoc Lab Anim Sci. 2013 Jan;52(1):34-43
pubmed: 23562031
Nephron Exp Nephrol. 2006;104(1):e6-e14
pubmed: 16707910
Mol Med Rep. 2017 May;15(5):2695-2702
pubmed: 28447737
Phytother Res. 2007 Nov;21(11):1020-4
pubmed: 17622973
Mol Med Rep. 2014 Sep;10(3):1455-60
pubmed: 25059399
Neurologist. 2009 Sep;15(5):268-73
pubmed: 19741433
Methods Enzymol. 1984;105:121-6
pubmed: 6727660